With its blockbuster Trikafta set to lose patent protection within the decade, Vertex is strengthening its cystic fibrosis ...

Vertex Pharmaceuticals said on Tuesday its next-generation cystic fibrosis treatment has won European Union approval for a ...

Biocon Biologics was granted marketing authorisation by the European Commission for Vevzuo and Evfraxy biosimilars of Denosumab used in the treatment of different bone diseases.

Biocon Ltd's arm, Biocon Biologics Ltd, has received European Commission authorisation for its Vevzuo and Evfraxy biosimilars ...

Aurobindo Pharma's subsidiary, CuraTeQ Biologics, secured European Commission approval for its trastuzumab biosimilar, ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

European Commission Approves Biocon Biologics’ Denosumab BiosimilarsBengaluru, Karnataka, India, July 3, 2025 Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary ...

Hyderabad: Aurobindo Pharma has announced that CuraTeQ Biologics, a wholly owned step-down subsidiary of the company, has ...

Canalevia® (crofelemer delayed-release tablets), under the name Canalevia-CA1, is conditionally approved by the FDA for ...

Siena: Sun Pharma European partner Philogen S.p.A has voluntarily withdrawn the application for marketing authorization to ...

CuraTeQ Biologics, a unit of Aurobindo Pharma, has received EU approval to market Dazublys, its trastuzumab biosimilar for ...